Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Cullen Frost Bankers Inc.

Cullen Frost Bankers Inc. lessened its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 11.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 19,282 shares of the medical research company's stock after selling 2,391 shares during the quarter. Cullen Frost Bankers Inc.'s holdings in Charles River Laboratories International were worth $3,559,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in CRL. Virtu Financial LLC acquired a new stake in Charles River Laboratories International during the third quarter worth $601,000. JPMorgan Chase & Co. increased its stake in Charles River Laboratories International by 21.6% during the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock worth $95,086,000 after acquiring an additional 85,759 shares during the last quarter. State Street Corp increased its stake in Charles River Laboratories International by 2.0% during the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock worth $419,601,000 after acquiring an additional 41,421 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in Charles River Laboratories International by 3.4% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 111,995 shares of the medical research company's stock worth $22,060,000 after acquiring an additional 3,714 shares during the last quarter. Finally, Janus Henderson Group PLC increased its stake in Charles River Laboratories International by 7.6% during the third quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company's stock worth $9,064,000 after acquiring an additional 3,268 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Remove Ads

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, COO Birgit Girshick purchased 1,514 shares of the business's stock in a transaction on Thursday, February 20th. The shares were bought at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the purchase, the chief operating officer now directly owns 55,058 shares in the company, valued at approximately $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm's stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Stock Up 4.1 %

NYSE:CRL traded up $6.93 during midday trading on Friday, reaching $176.20. The company had a trading volume of 1,169,106 shares, compared to its average volume of 699,906. The firm has a market capitalization of $9.01 billion, a price-to-earnings ratio of 1,174.68, a PEG ratio of 4.54 and a beta of 1.45. The stock's fifty day simple moving average is $169.15 and its 200-day simple moving average is $185.63. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $274.77. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International's revenue was down 1.1% compared to the same quarter last year. During the same period last year, the business posted $2.46 earnings per share. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CRL has been the subject of several recent analyst reports. Bank of America cut their target price on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a research note on Friday, December 13th. TD Cowen raised their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a research note on Monday, November 11th. The Goldman Sachs Group lowered their price target on Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating for the company in a research report on Thursday, January 23rd. Robert W. Baird lowered their price target on Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating for the company in a research report on Thursday, February 20th. Finally, Barclays lowered their price target on Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating for the company in a research report on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $198.36.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).